Replies to post #34351 on Innovation Pharmaceuticals Inc (IPIX)

[bob smith]

That's why purisol will bridge and fill the gap.

Gl

[Pepsiman2001]

That is good info to tuck under the mattress for the future. Thanks

One thing I discovered about cancer trials, faster is not better. In fact, it's exactly the opposite. Best case scenario: preliminary data will not ready for 12 more months.

[steelyeye]

Exactly right, the longer the trial goes the better the chances of efficacy. We do not want any AEs attributed to K or early DLTs. The further the cohort progression without MTD, the better.

One thing I discovered about cancer trials, faster is not better. In fact, it's exactly the opposite.

That said, its hard to fault the wish expressed by many here (myself included) that we might see a pre or post ASCO PR with miraculous early activation of P21 announced, given the "early Qpcr tests" combined with excellent pre-clinicals.

I'm content to let the graph lines start to accelerate upwards at cohorts 6-7 for K, and the P trial will be getting started in a few weeks.

[govorchin]

we'll see. the game changer will be IF we get positive p21 news early. imo i am counting on dr menon. this should not be surprising to him.

gov

[petemantx]

What if they do not see any DLT's from increased dosage but also no improved results. Do they ever reach a point where they say enoughs enough and arbitrarily set the MTD way above the efficacy dosage at the level where they decided to stop the trial?

Why go an additional 6 months or so if the higher dosages don't do any better than lower dosages that work?

Any input would be appreciated.